Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: Bacteriocins and conjugated linoleic acid
Research highlights
► We review the role of microbial-produced bioactive substances in probiosis. ► Bacteriocins can contribute to the ability of a strain to compete and establish itself in the gut. ► Bacteriocins may also protect against gastrointestinal pathogens in vivo. ► Probiotic bacteria can also play an important role in fatty acid metabolism.
Introduction
It is estimated that the healthy human adult gastrointestinal tract (GIT) harbors approximately 1013 microorganisms (Ventura et al., 2009). Initially developed at birth, the intestinal microbiotia is primarily comprised of high proportions of such microorganisms as bifidobacteria which are thought to be selected by breast or formula milk in the first weeks of life (Fanaro et al., 2003, Martin et al., 2009). Development of the adult microbiota is consistent with dominating populations of Firmicutes (including genera of Clostridia and lactic acid bacteria) and Bacteroidetes, while Proteobacteria, Actinobacteria, Fusobacteria and Verrucomicrobia are present to a lesser extent (Eckburg et al., 2005). The complex intestinal biomass is predicted to consist of greater than 1000 different phylotypes comprised of both the permanent or autochthonous inhabitants which form the stable populations of the adult gut ecosystem, and the acquired allochthonous or transient flora, which are obtained from diet (such as probiotics) or from the environment. Probiotics are live microorganisms, most frequently species of lactobacilli and bifidobacteria, which when administered in adequate amounts, confer a health benefit on the host (FAO/WHO, 2001). Although such health benefits are strain-dependent (Helwig et al., 2006), a single daily oral administration of 109 bacterial colony forming units (CFU) has generally been accepted as the optimal probiotic dose based on detection of the organism in human feces (Tannock, 2003). However, in some instances higher quantities may be required (Gionchetti et al., 2007, Larsen et al., 2006, Lee and Lee, 2009, Mimura et al., 2004), and thus the efficacious dosage may also be regarded as strain-dependent.
The intestinal microbiota is thought to have an integral role in human nutrition, metabolism, epithelial development, immune modulation, regulation of fat storage and protection against pathogens (Backhed et al., 2004, Claus et al., 2008, Corr et al., 2007, Lee et al., 2003, Martin et al., 2010, Martin et al., 2008b, Wells et al., 2010). Indeed, fluctuations in the composition of the intestinal ecosystem have been associated with various disease states including inflammatory immune disorders, obesity and cancer (Backhed, 2010, Davis and Milner, 2009, Scanlan et al., 2006). In this respect, probiotic interventions may beneficially influence the intestinal microbial ecology, intestinal homeostasis and host metabolism and, ultimately, the health of the host. Strain-specific microbial derived bioactive molecules, collectively termed “pharmabiotics” which include live or dead microorganisms as well as bacterial constituents and metabolites, may mediate many such interactions within the GIT (Shanahan et al., 2009). For example, production of antimicrobial peptides such as bacteriocins may beneficially modulate the intestinal ecology by the specific inhibition of pathogens (Corr et al., 2007).
Probiotics interact with the intestinal epithelial cells directly via cell components such as DNA, lipoteichoic acids and cell-surface polysaccharides (Ghadimi et al., 2010, Jijon et al., 2004, Lebeer et al., 2010, Pedersen et al., 2005) but also indirectly, through the production of bioactive metabolites (Heuvelin et al., 2009, Menard et al., 2004, Tao et al., 2006, Yan et al., 2007). Microbial-derived peptides and polysaccharides can activate signaling pathways and influence factors such as cytokine secretion and gut permeability, thereby enhancing epithelial barrier function. For example, a bioactive peptide secreted by Bifidobacterium infantis increased transepithelial resistance of human T84 cells by altering the expression of tight junction proteins (claudins and occludin) and cytokines (IFN-γ) via a mitogen-activated protein (MAP)-kinase-dependent mechanism (Ewaschuk et al., 2008). B. infantis conditioned medium also reduced colonic permeability and improved colitis in IL-10 deficient mice (Ewaschuk et al., 2008). Furthermore, the anti-inflammatory activity mediated by a bioactive polysaccharide PSA produced by the gut commensal Bacteriodes fragilis protected mice against Helicobacter hepaticus induced colitis (Mazmanian et al., 2008). Therefore, certain members of the intestinal microbiota can enhance gut barrier function and maintain intestinal homeostasis indicating a potential therapeutic role for probiotics in the prevention and treatment of gastrointestinal diseases.
In addition to having local effects in the gut, the intestinal microbiota is thought to possess the capacity to influence the overall metabolic homeostasis of the host. Indeed, germ-free mice exhibited altered metabolic profiles of the colon, liver and kidney compared with conventional animals (Claus et al., 2008). The colon of germ-free animals was characterized by an increase in raffinose and reduced levels of amino acids, ammonia, 5-aminovalerate and short chain fatty acids (SCFA) as well as other metabolites involved in energy pathways (Claus et al., 2008). Moreover, elevated levels of taurine, trimethylamine-N-oxide (TMAO) and bile acids were evident in the liver of germ-free animals. In addition, higher levels of choline, betaine, myo-inositol and scyllo-inositol in the kidneys of germ-free mice were linked with a hypertonic environment which was associated with renal dysfunction in previous studies (Claus et al., 2008). Indeed the extensive metabolic capability of intestinal microorganisms, such as bifidobacteria, is thought to provide them with a competitive advantage within the GIT. For example, it was recently suggested that the predominance of Bifidobacterium breve populations characteristic of the infant microbiota may be attributed to an operon dedicated to the degradation of starch, amylopectin and pullulan exclusively present in this species (Kleerebezem and Vaughan, 2009). This undoubtedly contributes to the ability of bifidobacteria to colonize early in life given that human milk and colostrum contain a wide variety of complex sugars. It has also been established that interventions with such probiotic strains can modulate the metabolic phenotype of the host in a very specific manner. For instance, the administration of Lactobacillus paracasei or Lactobacillus rhamnosus (in the presence or absence of galactosyl oligosaccharide prebiotics) increased bifidobacteria and reduced Clostridium perfringens and Staphylococcus aureus populations of germ-free mice inoculated with a model of human baby microbiota compared with control animals (Martin et al., 2008a, Martin et al., 2008b). The resulting alterations in lipid metabolism involved a decrease in hepatic triglycerides and an increase in long chain poly unsaturated fatty acids (PUFA) and correlated with a reduction in plasma lipoprotein levels. The modulation of amino acid, methylamine and SCFA metabolism as well as glycogenesis and gluconeogenesis was also reported upon exposure to the probiotics (Martin et al., 2008a, Martin et al., 2008b). As discussed in greater detail below, the gut microbiota may also modulate the fatty acid composition of the liver, brain and adipose tissue of the host via synthesis of bioactive fatty acids such as conjugated linoleic acid (CLA) (Wall et al., 2010, Wall et al., 2009). Anti-inflammatory and anti-cancer properties are among the wide array of health-promoting effects associated with isomers of CLA (Cook et al., 1993, Ha et al., 1987). Therefore, production of such bioactive metabolites may also be considered an important probiotic trait.
It is thus evident that the commensal microbiota has an almost infinite potential for metabolite production, many of these are pharmabiotic substances which can positively influence human health. In this review, we specifically examine the ability of the gut flora to produce antimicrobial peptides, namely bacteriocins, and bioactive fatty acids such as CLA and discuss their contribution to probiotic functionality.
Section snippets
Conclusions and potential for the future
Undeniably, the intestinal microbiota is a virtually unlimited source of pharmabiotic molecules. This review focused on the role of two distinct pharmabiotic families, bacteriocins and isomers of CLA, in probiosis and importantly, evidence was found to support the production and bioactivity of each of these metabolites in vivo. However, short chain fatty acids such as acetate, propionate and butyrate as well as γ-aminobutyric acid (GABA) are a major energy source for the body which also possess
Acknowledgments
Eileen O'Shea is in receipt of a Teagasc Walsh Fellowship. This work was funded by the Food Institutional Research Measure of the Department of Agriculture, Fisheries and Food (grant no. 04R & DC), and the Alimentary Pharmabiotic Centre (which is funded by the Science Foundation of Ireland (SFI), through the Irish Government's National Development Plan). The authors and their work were supported by SFI (grant no. 07/CE/B1368).
References (251)
- et al.
Molecular mechanism of transcription inhibition by peptide antibiotic microcin J25
Molecular Cell
(2004) - et al.
Production of free conjugated linoleic acid by Lactobacillus acidophilus and Lactobacillus casei of human intestinal origin
Journal of Dairy Science
(2003) - et al.
The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens
FEMS Immunology and Medical Microbiology
(2004) - et al.
Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease
Gastroenterology
(2004) - et al.
The polypeptide core of microcin E492 stably associates with the mannose permease and interferes with mannose metabolism
Research in Microbiology
(2010) - et al.
Conjugated linoleic acid in humans: regulation of adiposity and insulin sensitivity
The Journal of Nutrition
(2003) - et al.
Dietary sources of conjugated dienoic isomers of linoleic acid, a newly recognized class of anticarcinogens
Journal of Food Composition and Analysis
(1992) - et al.
Conjugated linoleic acid (9,11- and 10,12-octadecadienoic acid) is produced in conventional but not germ-free rats fed linoleic acid
The Journal of Nutrition
(1994) - et al.
Immune modulation by altered nutrient metabolism: nutritional control of immune-induced growth depression
Poultry Science
(1993) - et al.
In vivo study on the effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting Listeria monocytogenes
International Journal of Food Microbiology
(2009)
Gastrointestinal microflora, food components and colon cancer prevention
The Journal of Nutritional Biochemistry
Colicin M exerts its bacteriolytic effect via enzymatic degradation of undecaprenyl phosphate-linked peptidoglycan precursors
Journal of Biological Chemistry
Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma
The Journal of Nutrition
Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice
The Journal of Nutrition
In vitro inhibition of Escherichia coli O157:H7 by bifidobacterial strains of human origin
International Journal of Food Microbiology
Conjugated linoleic acid is synthesized endogenously in lactating dairy cows by Delta(9)-desaturase
The Journal of Nutrition
Chemical structure and translation inhibition studies of the antibiotic microcin C7
The Journal of Biological Chemistry
Development of dairy based functional foods enriched in conjugated linoleic acid with special reference to rumenic acid
Cytotoxic effects of pyocin S2 produced by Pseudomonas aeruginosa on the growth of three human cell lines
Canadian Journal of Microbiology
Microcin 15m from Escherichia coli: mechanism of antibiotic action
Antimicrobial Agents and Chemotherapy
Microcin 15n: a second antibiotic from Escherichia coli LP15
The Journal of Antibiotics (Tokyo)
Antibacterial activity associated with Bifidobacterium bifidum
Cultured Dairy Products Journal
HPLC purification and re-evaluation of chemical identity of two circular bacteriocins, gassericin A and reutericin 6
Letters in Applied Microbiology
Involvement of enterobactin synthesis pathway in production of microcin H47
Antimicrobial Agents and Chemotherapy
99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: the normal gut microbiota in health and disease
Clinical and Experimental Immunology
The gut microbiota as an environmental factor that regulates fat storage
Proceedings of the National Academy of Sciences of the United States of America
Salivaricin P: one of a family of two component anti-listerial bacteriocins produced by intestinal isolates of Lactobacillus salivarius
Applied and Environmental Microbiology
Rapid screening method for analyzing the conjugated linoleic acid production capabilities of bacterial cultures
Applied and Environmental Microbiology
Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease
Current Opinion in Clinical Nutrition and Metabolic Care
Post-translational heterocyclic backbone modifications in the 43-peptide antibiotic microcin B17. Structure elucidation and NMR study of a 13C,15N-labelled gyrase inhibitor
European Journal of Biochemistry
Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins
Applied and Environmental Microbiology
Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action
Annual Review of Nutrition
Bactericidal activity of both secreted and nonsecreted microcin E492 requires the mannose permease
Journal of Bacteriology
Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5
Applied and Environmental Microbiology
Molecular and genetic characterization of a novel bacteriocin locus in Enterococcus avium isolates from infants
Applied and Environmental Microbiology
Structural analysis and proteolytic activation of Enterococcus faecalis cytolysin, a novel lantibiotic
Molecular Microbiology
Characterization of the cvaA and cvi promoters of the colicin V export system: iron-dependent transcription of cvaA is modulated by downstream sequences
Journal of Bacteriology
A new colicin that adsorbs to outer-membrane protein Tsx but is dependent on the tonB instead of the tolQ membrane transport system
Joural of General Microbiology
Structure of colicin I receptor bound to the R-domain of colicin Ia: implications for protein import
The EMBO Journal
A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters
Journal of Applied Microbiology
Colicin biology
Microbiology and Molecular Biology Reviews
A five-strain probiotic combination reduces pathogen shedding and alleviates disease signs in pigs challenged with Salmonella enterica serovar Typhimurium
Applied and Environmental Microbiology
Effects of temperature and of heat shock on the expression and action of the colicin A lysis protein
Journal of Bacteriology
Mutacin II, a bactericidal antibiotic from Streptococcus mutans
Antimicrobial Agents and Chemotherapy
Human tumor cells are selectively inhibited by colicins
Folia Microbiologica
Conjugated linoleic acid isomers: differences in metabolism and biological effects
Biofactors
Biochemical and genetic evidence that Enterococcus faecium L50 produces enterocins L50A and L50B, the sec-dependent enterocin P, and a novel bacteriocin secreted without an N-terminal extension termed enterocin Q
Journal of Bacteriology
Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes
Molecular Systems Biology
Conjugated linoleic acid biosynthesis by human-derived Bifidobacterium species
Journal of Applied Microbiology
Intestinal bifidobacteria that produce trans-9, trans-11 conjugated linoleic acid: a fatty acid with antiproliferative activity against human colon SW480 and HT-29 cancer cells
Nutrition and Cancer
Cited by (227)
Ameliorating role of Tetrastigma hemsleyanum polysaccharides in antibiotic-induced intestinal mucosal barrier dysfunction in mice based on microbiome and metabolome analyses
2023, International Journal of Biological MacromoleculesGut Microbiota-Targeted Interventions in the Management of Chronic Kidney Disease
2023, Seminars in NephrologyCurrent status of probiotic and related health benefits
2022, Applied Food Research